Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Stock Has Average Target Price of $56.25 According to Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Sensei Biotherapeutics, with 12 buy ratings, two strong-buy ratings, one hold and one sell. The average 12-month price target is $56.25, well above the reported $19.44 share price.
• Institutional investors and hedge funds have increased exposure, with recent purchases by Citadel Advisors, Alyeska Investment Group and Stempoint Capital. Institutional ownership stands at 10.50%.
• Sensei reported a quarterly loss of $2.84 per share, beating the consensus estimate of a $5.04 loss. The clinical-stage biotechnology company is developing cancer immunotherapies, including its lead SNS-101 antibody program.

Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the sixteen analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $56.25.

A number of research analysts recently commented on FTH shares. Oppenheimer initiated coverage on Sensei Biotherapeutics in a report on Tuesday, July 28th. They issued an "outperform" rating and a $60.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 price target on shares of Sensei Biotherapeutics in a research note on Tuesday, August 11th. JonesTrading assumed coverage on shares of Sensei Biotherapeutics in a research report on Tuesday, August 4th. They set a "buy" rating and a $55.00 price target for the company. BTIG Research reissued a "buy" rating and issued a $55.00 price target on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. Finally, Robert W. Baird initiated coverage on shares of Sensei Biotherapeutics in a report on Friday, June 26th. They issued an "outperform" rating and a $57.00 price objective on the stock.

Institutional Investors Weigh In On Sensei Biotherapeutics

Institutional investors have recently modified their holdings of the company. Citadel Advisors LLC purchased a new stake in Sensei Biotherapeutics during the second quarter worth about $307,000. Renaissance Technologies LLC increased its stake in Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company's stock worth $1,010,000 after buying an additional 20,525 shares during the period. Bank of America Corp DE raised its position in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock valued at $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in Sensei Biotherapeutics during the 2nd quarter worth approximately $3,610,000. Finally, Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics during the first quarter worth $4,188,000. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Stock Up 3.4%

Shares of FTH opened at $19.44 on Tuesday. Sensei Biotherapeutics has a 52-week low of $7.45 and a 52-week high of $42.14. The firm has a market cap of $502.33 million, a P/E ratio of -0.14 and a beta of -0.29. The business has a fifty day moving average of $31.21.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($5.04) by $2.20. On average, equities analysts expect that Sensei Biotherapeutics will post -13.69 EPS for the current year.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company's approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients' responses to existing cancer treatments.

Sensei's pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.